Efficacy of Bromhexine versus Standard of Care in Reducing Viral Load in Patients with Mild-to-Moderate COVID-19 Disease Attended in Primary Care: A Randomized Open-Label Trial
et al., Journal of Clinical Medicine, doi:10.3390/jcm12010142, EudraCT2021-001227-41
, Efficacy of Bromhexine versus Standard of Care in Reducing Viral Load in Patients with Mild-to-Moderate.., Journal of Clinical Medicine, doi:10.3390/jcm12010142, EudraCT2021-001227-41
RCT 191 low risk (no mortality) outpatients in Spain, showing no significant differences with bromhexine. Authors note that "statistical differences between the study groups were observed in the percentage of patients treated with bronchodilators (p = 0.033) and receiving symptomatic treatment (p = 0.034), which were higher in the SOC alone group", but do not provide details or perform adjustments. There were more moderate/severe cases in the treatment group (9 vs. 5). Many results appear to be missing including: reduction in the severity of each symptom (0–10 NRS score) at days 4, 7, 14, and 28 as compared with baseline; proportion of patients with clinical improvement and time to clinical improvement; proportion of patients with disappearance of each symptom at days 4, 7, 14, and 28, and time to disappearance; proportion of asymptomatic patients at days 4, 7, 14, and 28.Bromhexine 48 mg/day for seven days. SOC included acetaminophen.Bromhexine may be less effective for omicron due to the entry process moving towards TMPRSS2-independent fusion.
|
risk of oxygen therapy, 67.3% lower, RR 0.33, p = 0.49, treatment 0 of 98 (0.0%), control 1 of 93 (1.1%), NNT 93, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
|
risk of hospitalization, 67.3% lower, RR 0.33, p = 0.49, treatment 0 of 98 (0.0%), control 1 of 93 (1.1%), NNT 93, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
|
risk of no recovery, 71.2% lower, RR 0.29, p = 0.33, treatment 1 of 52 (1.9%), control 3 of 45 (6.7%), NNT 21, dyspnea.
|
|
risk of no recovery, 186.5% higher, RR 2.87, p = 1.00, treatment 1 of 52 (1.9%), control 0 of 45 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), fever.
|
|
viral load, 6.6% higher, relative load 1.07, p = 0.82, treatment mean 13.54 (±26.02) n=98, control mean 14.43 (±26.94) n=93, relative change in ORF1ab Ct value, day 4, primary outcome.
|
|
viral load, 17.4% lower, relative load 0.83, p = 0.60, treatment mean 6.36 (±17.05) n=98, control mean 7.7 (±18.47) n=93, relative change in N Ct value, day 4, primary outcome.
|
|
viral load, 41.5% higher, relative load 1.41, p = 0.32, treatment mean 9.74 (±29.54) n=98, control mean 13.78 (±26.81) n=93, relative change in S Ct value, day 4, primary outcome.
|
|
risk of no viral clearance, 13.4% lower, RR 0.87, p = 0.31, treatment 52 of 98 (53.1%), control 57 of 93 (61.3%), NNT 12, day 14.
|
|
risk of no viral clearance, 13.6% higher, RR 1.14, p = 0.21, treatment 73 of 98 (74.5%), control 61 of 93 (65.6%), day 7.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Vila Méndez et al., 24 Dec 2022, Randomized Controlled Trial, Spain, peer-reviewed, 38 authors, trial EudraCT2021-001227-41.
Contact:
ana.martinez@csic.es (corresponding author), bsoler@ecbio.net.
Efficacy of Bromhexine versus Standard of Care in Reducing Viral Load in Patients with Mild-to-Moderate COVID-19 Disease Attended in Primary Care: A Randomized Open-Label Trial
Journal of Clinical Medicine, doi:10.3390/jcm12010142
A 28-day randomized open-label multicenter study was conducted to assess the efficacy of bromhexine plus standard of care (SOC) (n = 98) vs. SOC alone (n = 93) in 191 outpatients with mildto-moderate COVID-19 in the primary health care setting. Bromhexine three daily doses of 10 mL (48 mg/day) were administered for seven days. The primary efficacy endpoint was the reduction of viral load estimated as the cycle thresholds (Ct) to detect ORF1ab, N Protein, and S Protein genes by RT-qPCR in saliva samples on day 4 as compared with baseline. Ct values of the three genes increased from baseline throughout days 4 to 14 (p < 0.001) but significant differences between the study groups were not found. Differences in the percentages of patients with low, medium, and high viral loads at 4, 7, and 14 days were not found either. In summary, treatment with bromhexine plus SCO was associated with a viral load reduction of ORF1ab, N Protein, and S Protein genes at day 4, which was not significantly different than similar viral load reductions observed with SOC alone. The present findings do not seem to favor the use of bromhexine as an antiviral in patients with COVID-19.
Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Conflicts of Interest: A. Martínez and C. Gil are employees of the sponsor Agencia Estatal Consejo Superior de Investigaciones Científicas, M.P. (CSIC); B. Soler López was contracted to carry out the design, monitoring, statistical analysis and management of the publications derived from the study. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
Al-Kuraishy, ; A-Niemi, Hussain, Al-Gaareb, Lugnier, The potential role of bromhexine in the management of COVID-19: Decipher and a real game-changer, Curr. Med. Drug Res, doi:10.53517/CMDR.2581-5008.512021212
Alegria-Arcos, Barbosa, Sepúlveda, Combariza, González et al., Network pharmacology reveals mechanism of action of drugs to be repurposed for COVID-19, Front. Pharmacol, doi:10.3389/fphar.2022.952192
Anderson, Heesterbeek, Klinkenberg, Hollingsworth, How will country-based mitigation measures influence the course of the COVID-19 epidemic?, Lancet, doi:10.1016/S0140-6736(20)30567-5
Ansarin, Tolouian, Ardalan, Taghizadieh, Varshochi et al., Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial, Bioimpacts, doi:10.34172/bi.2020.27
Ashour, Abo Elmaaty, Sarhan, Elkaeed, Moussa et al., A systematic Review of the global intervention for SARS-CoV-2 combating: From drugs repurposing to molnupiravir approval, Drug Des. Dev. Ther, doi:10.2147/DDDT.S354841
Bahadoram, Keikhaei, Bahadoram, Mahmoudian-Sani, Hassanzadeh et al., Bromhexine is a potential drug for COVID-19; From hypothesis to clinical trials, Probl. Virol, doi:10.36233/0507-4088-106
Depfenhart, De Villiers, Lemperle, Meyer, Di Somma, Potential new treatment strategies for COVID-19: Is there a role for bromhexine as add-on therapy?, Intern. Emerg. Med, doi:10.1007/s11739-020-02383-3
Fu, Zheng, Zhou, Tang, Chen et al., Re-recognizing bromhexine hydrochloride: Pharmaceutical properties and its possible role in treating pediatric COVID-19, Eur. J. Clin. Pharmacol, doi:10.1007/s00228-020-02971-4
Gil, Ginex, Maestro, Nozal, Barrado-Gil et al., COVID-19: Drug Targets and Potential Treatments, J. Med. Chem, doi:10.1021/acs.jmedchem.0c00606
Ginex, Garaigorta, Ramírez, Castro, Nozal et al., Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods, Pharmaceuticals, doi:10.3390/ph14040332
Glowacka, Bertram, Müller, Allen, Soilleux et al., Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response, J. Virol, doi:10.1128/JVI.02232-10
Habtemariam, Nabavi, Ghavami, Cismaru, Berindan-Neagoe et al., Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2, Pharmacol. Res, doi:10.1016/j.phrs.2020.104853
Hoffmann, Kleine-Weber, Schroeder, Krüger, Herrler et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, doi:10.1016/j.cell.2020.02.052
Hörnich, Großkopf, Schlagowski, Tenbusch, Kleine-Weber et al., SARS-CoV-2 and SARS-CoV spike-mediated cell-cell fusion differ in their requirements for receptor expression and proteolytic activation, J. Virol, doi:10.1128/JVI.00002-21
Maggio, Corsini, Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection, Pharmacol. Res, doi:10.1016/j.phrs.2020.104837
Matsuyama, Nao, Shirato, Kawase, Saito et al., Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells, doi:10.1073/pnas.2002589117
Mikhaylov, Lyubimtseva, Vakhrushev, Stepanov, Lebedev et al., Bromhexine hydrochloride prophylaxis of COVID-19 for medical personnel: A randomized open-label study, Interdiscip. Perspect. Infect. Dis, doi:10.1155/2022/4693121
Shen, Mao, Wu, Tanaka, Zhang, TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections, Biochimie, doi:10.1016/j.biochi.2017.07.016
Tolouian, Mulla, Jamaati, Babamahmoodi, Marjani et al., Effect of bromhexine in hospitalized patients with COVID-19, J. Investig. Med, doi:10.1136/jim-2020-001747
Wang, Zhang, Chen, Xue, Zhang et al., Evaluating the efficacy and safety of bromhexine hydrochloride tablets in treating pediatric COVID-19: A protocol for meta-analysis and systematic review, Medicine, doi:10.1097/MD.0000000000022114
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.